Osteoblastoma is a benign aggressive primary bone tumor that occasionally presents
in the hand. Because surgical treatment remains the mainstay of treatment, there are
no established nonsurgical pharmacological options for patients in whom resection
is not feasible. Novel therapies, such as denosumab, are currently being investigated
in primary bone tumors. We report a case of osteoblastoma of the first metacarpal
that was successfully treated with denosumab. The patient showed a rapid and dramatic
response to treatment that led to the transformation of a locally destructive tumor
into an ossified painless mass, restoring function while avoiding surgery.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Hand SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The spectrum of osteoblastoma.AJR Am J Roentgenol. 1976; 126: 321-325
- Osteoblastoma: clinicopathologic study of 306 cases.Hum Pathol. 1994; 25: 117-134
- Osteoblastoma response to radiotherapy and chemotherapy.Med Pediatr Oncol. 1997; 28: 304-309
- Radiotherapy in the treatment of osteoblastoma—a report of 5 consecutive cases.Nowotwory J Oncol. 2004; 54: 31-33
- Clinical use of denosumab for the treatment of post-menopausal osteoporosis.Curr Med Res Opin. 2010; 26: 2807-2812
- Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.J Clin Oncol. 2009; 27: 1564-1571
- Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.Ann Surg Oncol. 2015; 22: 2860-2868
- Efficacy of denosumab in joint preservation for patients with giant cell tumor of the bone.Eur J Cancer. 2016; 59: 1-12
- Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.Ann Oncol. 2015; 26: 2149-2154
- Not all non-rheumatoid patients are satisfied with thumb metacarpophalangeal joint arthrodesis.J Plast Surg Hand Surg. 2013; 47: 144-146
- An electron microscopic study on osteoblastoma—ultrastructure and fine localization of alkaline phosphatase [in Japanese].Nippon Seikeigeka Gakkai Zasshi. 1992; 66: 1221-1231
- RANK ligand is a prerequisite for cancer-associated osteolytic lesions.J Pathol. 2002; 198: 228-236
- The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.Endocrinology. 2000; 141: 4768-4776
- Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production.Cell Tissue Res. 1999; 298: 327-334
- The RANK/RANKL/OPG triad in cancer-induced bone diseases.Cancer Metastasis Rev. 2006; 25: 541-549
- Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.Clin Cancer Res. 2012; 18: 4415-4424
- Osteoblastoma.Arch Pathol Lab Med. 2010; 134: 1460-1466
- Morphological transformation of giant-cell tumor of bone after treatment with denosumab.JBJS Case Connect. 2016; 6: e74
- The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the freedom extension study.Osteoporos Int. 2015; 26: 2773-2783
Article info
Publication history
Published online: March 22, 2019
Accepted:
February 1,
2019
Received:
November 4,
2017
Footnotes
No benefits in any form have been received or will be received related directly or indirectly to the subject of this article.
Identification
Copyright
© 2019 by the American Society for Surgery of the Hand. All rights reserved.
